Virax Biolabs

Historical price data

Virax Biolabs is a public immunology diagnostics company focused on decoding the adaptive immune response to address unmet needs in chronic, post-infectious conditions such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Its strategy is built on a dual business model: providing research-use-only (RUO) products to the scientific community while advancing its core ViraxImmune™ platform toward FDA-regulated in-vitro diagnostics (IVDs). Key recent achievements include a clinical partnership with Emory University and preparations for an FDA pre-submission meeting, positioning the company to potentially deliver the first objective blood-based diagnostic for Post-Acute Infection Syndrome (PAIS).

Proprietary platform utilizing pathogen-specific peptide pools to stimulate T cells, coupled with high-sensitivity ELISpot/FluoroSpot assays, designed to profile functional cellular immune responses for diagnostic purposes.

Competition in RUO immunology reagents is intense with large, established players. In the clinical PAIS diagnostic space, competition is emerging but fragmented; Virax's first-mover focus on a functional T-cell assay and its progress toward FDA engagement provide a distinct, though unproven, competitive position.